At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 714 enrolled
Drug / intervention
placebo +1 moredrug
Likely dose
placebo 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Double-Blind, Placebo-Controlled, Multicenter Study With A 40 Week Follow Up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 Milligram (Mg) Twice Daily (BID) for Smoking Cessation in Subjects With Cardiovascular Disease
In Brief
A Phase 3 clinical trial evaluating placebo and Varenicline for Smoking Cessation. Completed, enrolled 714 participants across 39 sites in 15 countries.
Detailed Summary
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesArgentina, Australia, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Mexico, Netherlands, South Korea, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2006
Enrollment StartFeb 2006
Primary CompletionNov 2007
Study CompletionAug 2008
TodayJul 2026
First PostedJan 27, 2006
Enrollment StartFeb 1, 2006
Primary CompletionNov 1, 2007
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.4 years ago
Interventions
placebodrug
1 mg placebo twice daily by mouth for 12 weeks
Vareniclinedrug
1 mg twice daily by mouth for 12 weeks